RNA editing has emerged as a novel mechanism in cancer progression. The double stranded RNA-specific adenosine deaminase (ADAR) modifies the expression of an important proportion of genes involved in cell cycle control, DNA damage response (DDR) and transcriptional processing, suggesting an important role of ADAR in transcriptome regulation. Despite the phenotypic implications of ADAR deregulation in several cancer models, the role of ADAR on DDR and proliferation in breast cancer has not been fully addressed. Here, we show that ADAR expression correlates significantly with clinical outcomes and DDR, cell cycle and proliferation mRNAs of previously reported edited transcripts in breast cancer patients. ADAR's knock-down in a breast cancer c...
Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and ca...
Abstract Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by Adenosine DeAminases acting on doub...
Despite tremendous advances in targeted therapies against lung adenocarcinoma, the majority of patie...
Abstract Background Whole transcriptome RNA variant analyses have shown that adenosine deaminases ac...
It is well established that somatic mutations and escape of immune disruption are two essential fact...
The evolution of cancer cells is believed to be dependent on genetic or epigenetic alterations. Howe...
ADARs catalyze adenosine-to-inosine (A-to-I) editing of double-stranded RNA and regulate global gene...
Adenosine deaminase acting on RNA (ADAR) is an RNA-binding protein that deaminates adenosine (A) to ...
RNA editing by RNA specific adenosine deaminase acting on RNA (ADAR) is increasingly being found to ...
RNA editing by RNA specific adenosine deaminase acting on RNA (ADAR) is increasingly being found to ...
Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine, which is then recognized as...
Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine, which is then recognized as...
RESULTS: We characterized A to G(I) mRNA editing in 81 breast cell lines, showing increased editing ...
SummaryAdenosine deaminases acting on RNA (ADARs) convert adenosine to inosine, which is then recogn...
Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and ca...
Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and ca...
Abstract Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by Adenosine DeAminases acting on doub...
Despite tremendous advances in targeted therapies against lung adenocarcinoma, the majority of patie...
Abstract Background Whole transcriptome RNA variant analyses have shown that adenosine deaminases ac...
It is well established that somatic mutations and escape of immune disruption are two essential fact...
The evolution of cancer cells is believed to be dependent on genetic or epigenetic alterations. Howe...
ADARs catalyze adenosine-to-inosine (A-to-I) editing of double-stranded RNA and regulate global gene...
Adenosine deaminase acting on RNA (ADAR) is an RNA-binding protein that deaminates adenosine (A) to ...
RNA editing by RNA specific adenosine deaminase acting on RNA (ADAR) is increasingly being found to ...
RNA editing by RNA specific adenosine deaminase acting on RNA (ADAR) is increasingly being found to ...
Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine, which is then recognized as...
Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine, which is then recognized as...
RESULTS: We characterized A to G(I) mRNA editing in 81 breast cell lines, showing increased editing ...
SummaryAdenosine deaminases acting on RNA (ADARs) convert adenosine to inosine, which is then recogn...
Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and ca...
Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and ca...
Abstract Adenosine-to-inosine (A-to-I) RNA editing, catalyzed by Adenosine DeAminases acting on doub...
Despite tremendous advances in targeted therapies against lung adenocarcinoma, the majority of patie...